Benetou Despoina-Rafailia, Vlachakis Panayotis K, Varlamos Charalampos, Alexopoulos Dimitrios
Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School Athens, Greece.
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital Athens, Greece.
US Cardiol. 2021 May 20;15:e09. doi: 10.15420/usc.2020.31. eCollection 2021.
The optimal antithrombotic treatment in patients receiving oral anticoagulation undergoing percutaneous coronary intervention (PCI) has been a field of intensive research. Although triple antithrombotic therapy had been, until lately, the strategy of choice, recent evidence points to the superiority of dual antithrombotic therapy regarding bleeding prevention, without significantly compromising efficacy. In the further challenging scenario of complex PCI, associated with a higher ischemic risk, the efficacy of an aspirin-free strategy, adopted shortly after the index event is under question, rendering decision-making a fairly difficult scenario for clinicians. Since patients with an indication for oral anticoagulation undergoing complex PCI are underrepresented in randomized trials, there are scarce data regarding the optimal treatment strategy in such patients. This review aims to analyze and compare different approaches regarding the type and duration of antithrombotic regimens, focusing on both safety and efficacy outcomes, as well as to discuss recent guidelines' suggestions regarding the therapeutic approach in patients receiving oral anticoagulation undergoing PCI procedures of increased complexity.
接受口服抗凝治疗的患者在进行经皮冠状动脉介入治疗(PCI)时的最佳抗栓治疗一直是深入研究的领域。尽管直到最近,三联抗栓治疗一直是首选策略,但最近的证据表明,在预防出血方面,双联抗栓治疗具有优越性,且在疗效上没有显著妥协。在与较高缺血风险相关的更具挑战性的复杂PCI情况下,在索引事件后不久采用的无阿司匹林策略的疗效受到质疑,这使得临床医生的决策相当困难。由于在随机试验中,有口服抗凝指征且接受复杂PCI的患者代表性不足,关于此类患者最佳治疗策略的数据很少。本综述旨在分析和比较抗栓方案的类型和持续时间的不同方法,重点关注安全性和疗效结果,并讨论近期指南中关于接受口服抗凝治疗且进行复杂性增加的PCI手术患者治疗方法的建议。